Archives of Medical Research
Volume 40, Issue 4 , Pages 256-263 , May 2009

Downregulation of HLA Class I Molecules in Primary Oral Squamous Cell Carcinomas and Cell Lines

  • Qiusha Tang

      Affiliations

    • The Key Laboratory of Developmental Genes and Human Disease of Education Ministry, Department of Genetics and Developmental Biology, Southeast University Medical School, Nanjing, Jiangsu Province, China
    • ,
  • Jianqiong Zhang

      Affiliations

    • The Key Laboratory of Developmental Genes and Human Disease of Education Ministry, Department of Genetics and Developmental Biology, Southeast University Medical School, Nanjing, Jiangsu Province, China
    • ,
  • Bing Qi

      Affiliations

    • Department of Pathology, Oral Hospital of Jiangsu Province, Nanjing, Jiangsu Province, China
    • ,
  • Chuanlai Shen

      Affiliations

    • The Key Laboratory of Developmental Genes and Human Disease of Education Ministry, Department of Genetics and Developmental Biology, Southeast University Medical School, Nanjing, Jiangsu Province, China
    • ,
  • Wei Xie

      Affiliations

    • The Key Laboratory of Developmental Genes and Human Disease of Education Ministry, Department of Genetics and Developmental Biology, Southeast University Medical School, Nanjing, Jiangsu Province, China
    • Corresponding Author InformationAddress reprint requests to: Wei Xie, Ph.D., The Key Laboratory of Developmental Genes and Human Disease of Education Ministry, Department of Genetics and Developmental Biology, Southeast University Medical School, 87 Dingjiaqiao Rd, Nanjing, Jiangsu Province, China 210009.

Received 6 December 2008 ,Accepted 30 March 2009.

References 

  1. Ruiz F, Garrido F. HLA and cancer: from research to clinical impact. Immunol Today. 1998;19:539–543
  2. Benitez R, Godelaine D, Lopez M, et al. Mutations of the β2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigen. 1998;52:520–523
  3. Blanchet O, Bourge F, Zinszner H, et al. DNA binding of regulatory factors interacting with MHC-class-I gene enhancer correlates with MHC-class-I transcriptional level in class-I-defective cell lines. Int J Cancer. 1991;6:138–141
  4. Owen B, Pease L. TAP association influences the conformation of nascent MHC class I molecules. J Immunol. 1999;162:4677–4680
  5. York A, Rock L. Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol. 1996;14:36–42
  6. Mattijssen V, Peters M, Schalkwijk L, et al. Expression in head and neck squamous-cell carcinoma is associated with clinical outcome. Int J Cancer. 1993;55:580–536
  7. Feenstra M, Veltkamp M, Kuik J, et al. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens. 1999;54:235–240
  8. Old M, Khan N, Verma I, et al. A multi-center study in order to further define the molecular basis of beta-thalassemia in Thailand, Pakistan, Sri Lanka, Mauritius, Syria, and India, and to develop a simple molecular diagnostic strategy by amplification refractory mutation system-polymerase chain reaction. Hemoglobin. 2001;25:397–345
  9. Stam J, Spits H, Ploegh L. Monoclonal antibodies raised against denatured HLA B locus heavy chains permit biochemical characterization of certain HLA C locus products. J Immunol. 1986;137:2299–2306
  10. Sernee F, Ploegh L, Schust J. Why certain antibodies cross-react with HLA A and HLA G: epitope mapping of two common MHC class I reagents. Mol Immunol. 1998;35:177–185
  11. Ibrahim C, Allory Y, Commo B, et al. Altered pattern of major histocompatibility complex expression in renal carcinoma. Am J Pathol. 2003;162:501–508
  12. Cabrera T, Lopez A, Gaforia J, et al. Analysis of HLA expression in human tumor tissues. Cancer Immunol Immunother. 2003;52:1–9
  13. Wang P, Vanky F, Klein E. Application of isoelectric focusing for studies of major histocompatibility complex class I antigen expression on human carcinomas. Cancer Immunol Immunother. 1991;33:65–72
  14. Palmisano L, Pistillo P, Capanni C, et al. Investigation of HLA class I downregulation in breast cancer by RT-PCR. Hum Immun. 2001;62:133–141
  15. Matsui M, Machida S, Itani T, et al. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-gamma. J Gastroenterol Hepatol. 2002;17:897–896
  16. Ramal M, Feenstra M, Zwan W, et al. Criteria to define HLA haplotype loss in human solid tumors. Tissue Antigens. 2000;55:443–452
  17. Maziarz T, Burakoff J, Faller V. The regulation of exogeneous and endogeneous class I MHC genes in a human tumor cell line, k562. Mol Immunol. 1990;27:135–146
  18. Feenstra M, Bakema J, Verdaasdonk M, et al. Detection of a putative HLA-A∗31012 processed (intronless) pseudogene in a laryngeal squamous cell carcinoma. Genes Chromosomes Cancer. 2000;27:26–38
  19. Tatake J, Zeff A. Regulated expression of the major histocompatibility complex class I genes. Proc Soc Exp Biol Med. 1993;203:405–412
  20. Elsen J, Peijnenburg A, Eggermond C. Shared regulatory elements in the promoters of MHC class I and class II genes. Immunol Today. 1998;19:308–310
  21. Matsui M, Ikeda M, Akatsuka T. High expression of HLA-A2 on an oral squamous cell carcinoma with down-regulated transporter for antigen presentation. Biochem Biophy Res Commun. 2001;280:1008–1019
  22. Cabrera M. The double role of the endoplasmic reticulum chaperone tapasin in peptide optimization of HLA class I molecules. Scand J Immunol. 2007;65:487–496
  23. Johnsen K, France J, Nagy N, et al. Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence. Int J Cancer. 2001;91:366–372
  24. Murakami Y, Kanda K, Yokota K, et al. Prognostic significance of immuno-proteosome subunit expression in patients with renal-cell carcinoma: a preliminary study. Mol Urol. 2001;5:113–121
  25. Eynde J, Morel S. Differential processing of class-restricted epitopes by the standard proteasome and the immunproteasome. Curr Opin Immunol. 2001;13:147–156
  26. Yang L, Lin Y. Determination of HLA-A, -B and -DRB1 haplotypes based on allelic homozygosity data in selected bone marrow donors of the Taiwanese marrow donor registry. Int J Immunol. 2007;34:385–393
  27. Seliger B, Hammers S, Hohne A, et al. IFN-γ-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. Clin Cancer Res. 1997;3:573–584
  28. Mazzon C, Baldani B, Cecchini P, et al. IFN-γ and R-848 dependent activation of human monocyte-derived dendritic cells by Neisseria meningitidis adhesin. A. J Immunol. 2007;179:3904–3912
  29. Pedron B, Guerin V, Jacquemard F, et al. Comparison of CD8+ T cell responses to cytomegalovirus between human fetuses and their transmitter mothers. J Infect Dis. 2007;196:1033–1041
  30. Eynde J, Morel S. Differential processing of class-restricted epitopes by the standard proteasome and the immunoproteasome. Curr Opin Immunol. 2001;13:147–152
  31. Cardozo L, Kohanski RA. Altered properties of the branched chain acid-preferring activity contribute to increased cleavage after branched chain residues by the immunoproteasome. J Biol Chem. 1998;273:16764–16776

PII: S0188-4409(09)00059-9

doi: 10.1016/j.arcmed.2009.04.004

Archives of Medical Research
Volume 40, Issue 4 , Pages 256-263 , May 2009

Article Tools

* Image Usage & Resolution